For drug therapy of obesity or overweight, obese patient can be prescribed with anorectic Metermine used in conjunction with exercise and hypocaloric diet. The only supplier of Metermine in Australia is a company iNova Pharmaceuticals, which is a part of Valeant Pharmaceuticals International since December 2011.
Active ingredient of Metermine is a sympathomimetic amine Phentermine, which is similar to amphetamine by its chemical structure and acts mainly on the hypothalamus. Namely, this brain region includes centers that regulate the feeling of hunger and satiety.
Metermine differs from other anorectic drugs by special formula of the active ingredient. In this drug, Phentermine is used as an ion-exchange resin complex that ensures its gradual release, as well as promotes a long-term appetite-suppressing effect.
Clinical studies have shown that this weight loss drug is rapidly absorbed from the gastrointestinal tract; herewith the half-life is about 25 hours that promotes a prolonged anorectic effect. Metermine is supplied in Australia in 15, 30 and 40mg capsules; each dosage of capsules has its original color.
Metermine 15 mg capsules have grey and green color and imprinted with “Metermine 15”, Metermine 30mg capsules are grey and reddish brown imprinted with “Metermine 30”. Metermine 40mg capsules – grey and orange imprinted with Metermine 40”.
The recommended starting dose for obesity treatment in adults is 30mg per day. A Metermine 30mg capsule or two Metermine 15mg capsules should be taken early in the day (for example, during breakfast). Avoid using this appetite suppressant drug in the evening, because the risk of insomnia and other sleep problems increases.
Maintenance dose is adjusted depending on the patient’s tolerance and responsiveness to Metermine. Obesity treatment can be carried out by two dosage regimens: continuous or intermittent. When prescribing continuous regimen, remember that the treatment duration should not exceed 3 months.
Intermittent regimen with Metermine can be carried out as follows: four weeks of systemic use of this weight loss drug are alternated with the similar period without medication. Herewith, the patient should always adhere to the established dosage.
Since the number of children and adolescents suffering from obesity annually increases, Metermine can be prescribed to adolescents aged 12 years and older in Australia. For obesity treatment in this age group, adult doses are used.
However, take into account that not every obese patient can use Metermine. In order not to provoke serious side effects, obese patients with hyperthyroidism, cerebrovascular disease and pulmonary artery hypertension are recommended to refuse using Metermine.
In addition, this drug should not be used in patients with moderate to severe arterial hypertension, glaucoma, and existing heart valve abnormalities or heart murmurs, since Metermine increases heart rate.
When prescribing Metermine to patients with mild hypertension, it is necessary to take caution and to monitor blood pressure in the first few days. If level of blood pressure increases and you cannot control it, reduce the dose of this anti-obesity drug, or stop using it.
Caution should be taken while using Metformin in patients receiving psychotropic drugs and in epileptic patients. To avoid the development of cardiovascular and cerebrovascular events, weight loss should be gradual. Metermine should not be taken in conjunction with other anti-obesity drugs.
According to reviews of many Australians, Metermine is well tolerated (if recommendations for use are observed). This drug has helped many obese people to effectively lose weight and change eating habits.